The European Commission (EC) has granted conditional marketing authorisation for Kinpeygo (budesonide) capsules for the treatment of primary immunoglobulin A nephropathy (IgAN).
The treatment involves adults at risk of rapid disease progression with a specific urine protein-to-creatinine ratio.
Kinpeygo is an orphan medicinal product and the first and only approved treatment for IgAN – a rare, progressive autoimmune disease of the kidney, with more than 50% of patients potentially progressing to end-stage renal disease. Through a partnership with developer Calliditas Therapeutics, Kinpeygo will be marketed in the European Economic Area (EEA) exclusively by Stada…
